FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway

Core Insights - AstraZeneca (AZN) and Daiichi Sankyo's supplemental biologics license application (sBLA) for Datroway has been accepted by the FDA for priority review, targeting expanded use in breast cancer treatment [2][4] - The FDA issued a complete response letter (CRL) for AstraZeneca's BLA for the subcutaneous formulation of Saphnelo, which is currently marketed as an IV infusion for systemic lupus erythematosus (SLE) [3][10] Group 1: Datroway Approval - The sBLA for Datroway seeks approval for treating adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not eligible for PD-1/PD-L1 inhibitor therapy [4] - Datroway is already approved for HR-positive, HER2-negative breast cancer and has shown statistically significant improvements in overall survival and reduced disease progression risk in the TROPION-Breast02 phase III study [5] - The FDA has set a target action date for the Datroway application in the second quarter of 2026 [5][7] Group 2: Saphnelo CRL - The FDA's CRL for Saphnelo's subcutaneous formulation was based on interim data from the phase III TULIP-SC study, which indicated a safety profile consistent with the IV formulation [10] - AstraZeneca has submitted additional information requested in the CRL and is working with the FDA, expecting a regulatory decision in the first half of 2026 [11] Group 3: Market Performance - Over the past year, AstraZeneca's shares have increased by 29.9%, slightly outperforming the industry average of 29.1% [6]